Surgical robotics company CMR Surgical has closed a financing round of over £150m through a combination of equity and debt capital.
The fundraising, which was supported by all the company’s existing major investors, includes a new debt investment from Trinity Capital.
CMR says it will use the funds to accelerate commercial expansion of the Versius Surgical Robotic System to more hospitals around the world – with a major focus on launching Versius in the United States – and to continue advancing surgical robotics innovation and product development, including the launch of Versius Plus.
Versius, the second most-utilised soft tissue surgical robot in the world, has been used to complete more than 30,000 surgical cases globally in more than 30 different countries across a wide range of specialities including colorectal, general, gynaecology, thoracic and urology surgeries.
CMR is also actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study, which is the world’s first multicentre prospective trial on the use of Versius in paediatric surgery, and a transoral robotic surgery (TORS) trial.
“CMR is a competitive, well-established company with a transformative product providing clear clinical value,” said CEO Massimiliano Colella.
“We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to give thanks to our CFO, Andre Nel, and the team for securing this financing to provide the foundation for realising our strategic vision of making robotic assisted surgery accessible to all patients who need it whilst accelerating future product development.
“I would also like to thank our investors for their continued support and look forward to delivering sustainable growth and life-changing solutions to the global healthcare community.”
Rob Lake, senior managing director, life sciences at Trinity Capital, added: “Trinity Capital is excited to partner with CMR Surgical at this important juncture. CMR has established itself as a trailblazer in surgical robotics, with Versius already proving its value to surgeons and patients worldwide.
“We are confident in CMR’s vision and leadership, and our investment reflects our belief that Versius will continue to drive a new era in minimally invasive surgery. We look forward to supporting CMR as it continues to scale and transform surgical care on a global level.”